Three new studies reveal recent advances in biliary tract and colorectal cancer screening and treatment

From ASCO Post Staff

Posted: 2023/5/9 10:46:00 AM

Last update: May 9, 2023 1:57:56 PM

get permission

Researchers have uncovered the impact of several new developments in screening and treating patients with biliary tract and colorectal cancer. This includes the development of patient-derived organoids to test chemotherapy response and the use of non-steroidal anti-inflammatory drugs (NSAIDs) to reduce risk. Preventing early-onset adenomas and implementing a lower screening age for colorectal cancer, according to his three new studies presented at Digestive Disease Week 2023.

Individualized drug screening in patient-derived organoids of biliary tract cancer

Chemotherapy is often the only treatment option for patients with biliary tract cancer. Biliary tract cancer is one of the deadliest cancers because it is usually discovered late. However, existing tools cannot effectively predict which chemotherapeutic agents will work best for individual patients in a limited amount of time. In the new study, researchers tested organoids derived from her 72 patients with her seven chemotherapy agents. The researchers then identified the gene signatures of organoids that respond to various agents and developed a gene panel test that predicts response to treatment. Screening results were first validated in mice implanted with the same tumor and subsequently confirmed in his 92% (n = 12/13) of patients treated with chemotherapeutic agents identified by this process. . Researchers say organoids may offer greater precision in personalized chemotherapy screening for biliary tract cancer patients, and gene panel testing may help select effective agents for individual patients. concluded that there is

NSAID use and risk of early-onset adenoma

The incidence of early-onset colorectal cancer in patients under the age of 50 is rising at an alarming rate. Emerging data suggest that aspirin use may be associated with a lower risk of early-onset colorectal cancer. However, researchers remain unclear whether regular use of aspirin or other NSAIDs may be associated with a reduced risk of early-onset adenomas, which are more likely to be malignant. In the new study, researchers analyzed her NSAID use data for her 32,058 patients from the Nurses’ Health Study II. The patient who participated in this study had at least one colonoscopy from 1991 to 2015 before he was 50 years old. The researchers noted that he found 1,247 early-onset adenomas, including 290 high-risk cases. They further found that regular NSAID use was associated with a reduced likelihood of developing both high-risk and low-risk adenomas. They emphasized that their new findings indicated the need for further evaluation of NSAIDs as promising agents for the prevention of early-onset colorectal cancer, given their favorable risk-benefit profile in younger patients. .

Factors Contributing to Mortality in Colorectal Cancer Patients

Colorectal cancer mortality continues to decline due to advances in screening and management strategies. Despite this downward trend, colorectal cancer remains one of the leading causes of cancer-related mortality in the United States. In a new study, researchers looked at the causes of death in 576 patients who underwent surgery for colorectal cancer between 2004 and 2018. Researchers found that colorectal cancer mortality gradually decreased over time. Cancer and systemic diseases increased over time. The researchers also identified patients who were more likely to die from colorectal cancer compared to other causes, including those who were younger, had fewer complications, and had distant metastases. Researchers say the recent revision to the screening age for colorectal cancer (lowering from 50 to 45) may be a step in the right direction to detect and treat the disease at an early stage. They emphasized that their findings support the idea that there is.

The content of this post has not been reviewed by the American Society of Clinical Oncology (ASCO®) and does not necessarily reflect the views or opinions of ASCO®.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *